Tyler D. Gavitt

Oct 18, 2023 | cell.com | David Martinez |David Martínez |Alexandra Schafer |Tyler D. Gavitt |Michael Mallory

Highlights • A trivalent RBD nanoparticle vaccine elicits broadly cross-reactive antibodies • Trivalent RBD nanoparticle vaccine elicits BA.1 and XBB.1.5 neutralizing antibodies • Vaccine-mediated protection against lethal SARS-CoV and pathogenic MERS-CoV • A single vaccine protects against group 2b/2c betacoronavirus challenge in mice Summary The emergence of three highly pathogenic human coronaviruses—severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003, Middle Eastern...

Oct 18, 2023 | cell.com | David Martinez |David Martínez |Alexandra Schafer |Tyler D. Gavitt |Michael Mallory

Highlights • A trivalent RBD nanoparticle vaccine elicits broadly cross-reactive antibodies • Trivalent RBD nanoparticle vaccine elicits BA.1 and XBB.1.5 neutralizing antibodies • Vaccine-mediated protection against lethal SARS-CoV and pathogenic MERS-CoV • A single vaccine protects against group 2b/2c betacoronavirus challenge in mice Summary The emergence of three highly pathogenic human coronaviruses—severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003, Middle Eastern...

May 23, 2023 | biorxiv.org | David Martinez |Alexandra Schaefer |Tyler D. Gavitt |Michael Mallory

Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.